Bayer establishes maize seed facility in Zambia

Bayer recently unveiled its new maize seed facility in Kabwe, Zambia

Through this US$34.7mn facility, Bayer has managed to triple its existing capacity for high-quality maize seed production in 2025. This capacity ultimately converts into annual maize consumption of approximately 30 million people in the region, and is expected to further increase in the coming years. 

The high-yielding seeds will reach 6.4 million smallholder farmers in Zambia and other countries in sub-Saharan Africa this year and up to 10 million by 2030. To date, the investment is the second largest private investment by a German company in Zambia. The site is a key component of Bayer’s growth strategy for Africa, with the aspiration of doubling the Crop Science Division’s business on the continent by 2030.

Bayer plans to employ 80 permanent staff members and over 100 seasonal workers and contractors at the site. Additionally, approximately 15,000 seasonal on-farm jobs will be generated through Bayer’s field operations and those of contract growers to produce the seeds. By addressing up to 10 million smallholder farmers, the investment significantly helps to advance Bayer’s goal of reaching 21.5 million smallholders in Africa and 100 million globally by 2030.

Bayer is also supporting the local healthcare system by funding the establishment of a new health centre, which aims to provide essential healthcare services to more than 10,000 residents, including Bayer employees and their dependents.

“Millions of people around the world, particularly in sub-Saharan Africa, suffer from severe food insecurity. Ending hunger is central to our mission at Bayer. With our new seed facility in Zambia, we want to make a meaningful contribution to that crucial goal,” said CEO Bill Anderson, who inaugurated the site alongside president of Zambia, Hakainde Hichilema. “The new facility will help us improve food security, empower smallholder farmers, and support communities in numerous countries on the African continent. It’s also a great business opportunity for Bayer. We can’t wait to ramp up production," Anderson concluded.